Latest research and what is coming
Real possibilities, honestly labeled. Every item shows how strong the evidence is and when we last checked it.
Every medical claim on this page links to its source. Last updated 15 November 2026. Educational information, not medical advice.
No published evidence establishes a cure for MPA. Nothing on this page is a recommendation. Trials have strict eligibility rules, and early results often do not hold up. Talk with your specialist before seeking any experimental treatment.
What changed recently (checked 15 Nov 2026)
- Avacopan: European Commission revoked the EU authorisation on 4 Aug 2026; U.S. withdrawal proposal still under FDA consideration, no final decision found. Details
- Iptacopan phase 2 interim kidney results presented at ASN Kidney Week, 24 Oct 2026.
- InflaRx outlined planned izicopan phase 2 trials (2027) in Nov 2026.
- VIS954 phase 2 registered (not yet recruiting).
How to read the badges
Approved regulator-approved for that use · Phase 3 large trial · Phase 2 mid-size trial · Early trial phase 1 or 1/2 · Case report one or a few people · Preclinical / lab / computational lab, computer or retrospective data · Safety or regulatory alert safety or regulatory action
"Company-reported" means the information comes from a press release or company filing, not a peer-reviewed paper. See how to read a study.
Treatments for active disease and relapse
Avacopan (Tavneos)
Approved (U.S., under proposed withdrawal)Safety or regulatory alertRevoked in EU (4 Aug 2026)
What it is: An oral medicine that blocks the C5a receptor, part of the complement system.
Status: FDA liver-injury safety communication; FDA's drug center proposed withdrawing U.S. approval on 27 Apr 2026, and the drug remains available while that is decided. The pivotal ADVOCATE trial paper was retracted on 29 Jun 2026. The European Commission revoked the EU marketing authorisation on 4 Aug 2026. 1,2,3,4
What this means for you now: Do not stop or change it on your own; talk with your prescriber. Full timeline.
Hope vs hype: Unsettled. We report facts and dates only.
Last checked 15 Nov 2026
CD19 CAR T-cell therapy (trial at Mass General)
Early trial (phase 1/2)
What it is: A person's own immune cells are engineered to remove B cells, then infused back. Used in some blood cancers; being studied in autoimmune disease.
Status: NCT07388277 (CC-97540) for ANCA-associated vasculitis: active, not recruiting; record updated 10 Sep 2026. 5
What this means for you now: Only available inside a trial. Not a cure.
Hope vs hype: Very early; no results posted.
Last checked 15 Nov 2026
CAR T case reports in ANCA vasculitis
Case report
What it is: Single-patient reports of CAR T therapy for vasculitis that did not respond to standard treatment.
Status: One person with relapsing GPA was in complete remission without further medicine at 12 months (Rheumatology 2026). One person with refractory MPO-ANCA vasculitis had kidney remission (Kidney Int Rep 2025). A congress abstract describes tandem CD19-BCMA CAR T in refractory AAV. A 2026 review summarizes the evidence. 6,7,8,9
What this means for you now: Striking results in one person at a time. Not available outside research; risks and long-term effects are unknown.
Hope vs hype: Highest hype risk on this page: results in single people, short follow-up, and unknown safety after a kidney transplant.
Last checked 15 Nov 2026
Obinutuzumab
Approved (lupus nephritis, not AAV)Phase 2 (AAV)
What it is: A newer antibody that removes B cells, like rituximab.
Status: FDA approved it for lupus nephritis in Oct 2025 (company-reported). In AAV: a phase 2 study of obinutuzumab beta with low-dose steroids in new ANCA glomerulonephritis (NCT07746180) is recruiting (updated 15 Sep 2026); the ObiVas trial compares it with rituximab in PR3-positive AAV (protocol published). 10,11,12
What this means for you now: Not approved for MPA. Only inside a trial.
Hope vs hype: A plausible next-generation option, but no AAV result yet.
Last checked 15 Nov 2026
Iptacopan
Phase 2
What it is: An oral complement factor B inhibitor (approved for some other kidney and blood conditions).
Status: NCT06388941 (Novartis): 84 randomized, with rituximab and steroid taper; active, not recruiting. Interim results at ASN Kidney Week (24 Oct 2026, abstract): urine protein fell earlier with iptacopan, complement markers dropped, and adverse events were similar. The main result (sustained remission at week 48) is not yet reported. 13,14
What this means for you now: Only inside a trial. Interim results are not final results.
Hope vs hype: Interim and surrogate measures only (a conference abstract).
Last checked 15 Nov 2026
Vilobelimab / BDB-001 (anti-C5a antibody)
Phase 2 (completed)Phase 3 (China)
What it is: An antibody that blocks C5a, a complement protein.
Status: Phase 2 IXCHANGE reported in 2021 (company-reported). A phase 3 trial of BDB-001 (NCT07168161, Staidson, China, 300 planned) is recruiting; the company expects data in the second half of 2028. 15,16,17
What this means for you now: Not available outside trials.
Hope vs hype: Company-reported; look for full peer-reviewed results.
Last checked 15 Nov 2026
Izicopan (oral C5a receptor inhibitor)
Planned (phase 2, 2027)
What it is: An oral medicine aimed at the same target as avacopan.
Status: InflaRx plans two phase 2 AAV trials starting in 2027, with first data expected in 2028 (company press release, Nov 2026). 17
What this means for you now: Not yet being tested in people with AAV.
Hope vs hype: Plans, not results.
Last checked 15 Nov 2026
VIS954 (Otsuka)
Phase 2
What it is: An investigational antibody being tested in moderate-to-severe active AAV.
Status: NCT07904806: not yet recruiting; updated 29 Oct 2026. 18
What this means for you now: Too early to say anything about benefit.
Hope vs hype: Registration only; no results.
Last checked 15 Nov 2026
PREP-ANCA (pre-emptive rituximab when ANCA returns)
Strategy trial
What it is: A trial asking a practical question: when ANCA reappears in remission, is it better to watch closely or give rituximab early?
Status: EU trial 2025-522049-23-00 is listed as Authorised (decision 8 Jun 2026). 19
What this means for you now: Does not change the usual approach today: a returning ANCA alone usually does not mean treatment.
Hope vs hype: Answers a question many patients ask; no results yet.
Last checked 15 Nov 2026
Belimumab
Negative trialMechanistic study
What it is: A medicine that targets a B-cell survival signal.
Status: In BREVAS, adding belimumab to standard maintenance did not significantly reduce relapse. COMBIVAS is a mechanistic study combining rituximab and belimumab in PR3-associated disease. 20,21
What this means for you now: Not used for MPA maintenance based on current evidence.
Hope vs hype: A useful reminder that not every promising idea works.
Last checked 15 Nov 2026
Ustekinumab (repurposing signal)
Case report (small series)Preclinical / lab / computational
What it is: An existing medicine for other immune diseases, chosen by profiling immune cells in kidney tissue.
Status: Researchers in Hamburg used immune profiling to target specific T cells and reported clinical responses in a few people with relapsing ANCA glomerulonephritis (Nat Commun 2024). 22
What this means for you now: Hypothesis only; not a treatment for MPA.
Hope vs hype: Hypothesis-generating; needs a controlled trial.
Last checked 15 Nov 2026
Transplant-related research
These are about protecting a transplanted kidney, not treating MPA itself.
Felzartamab (antibody-mediated rejection)
Phase 3
What it is: An anti-CD38 antibody being studied for late antibody-mediated rejection of a transplanted kidney.
Status: TRANSCEND (NCT06685757, Biogen): active, not recruiting (updated 5 Jun 2026). Long-term extension NCT07444489: enrolling by invitation (updated 2 Nov 2026). Phase 2 extension results published Sep 2026. 23,24,25
What this means for you now: A rejection medicine, not an MPA treatment.
Hope vs hype: Promising for a specific rejection type; phase 3 results not yet reported.
Last checked 15 Nov 2026
Imlifidase (desensitization)
Approved (EU, conditional)U.S. FDA decision expected
What it is: An enzyme that quickly cuts antibodies, to allow transplant for highly sensitized people with a positive crossmatch.
Status: Conditionally approved in the EU as Idefirix. U.S. application accepted Feb 2026; FDA action date set for 19 Dec 2026 (company-reported). 26,27
What this means for you now: Helps a small group get a transplant; not MPA-specific.
Hope vs hype: Real for a narrow group; not a vasculitis treatment.
Last checked 15 Nov 2026
Tegoprubart (anti-CD40L, transplant)
Phase 2Phase 3 (planned)
What it is: An antibody being studied as an alternative to tacrolimus after kidney transplant.
Status: Phase 3 LEGACY (NCT07835581, about 600 to 620 people): not yet recruiting; the company says it plans to start in Q4 2026. 28,29
What this means for you now: Only inside trials.
Hope vs hype: Phase 2 data are company-reported; phase 3 not started.
Last checked 15 Nov 2026
MDR-101 immune tolerance
Phase 3 (narrow setting)
What it is: A cell therapy aiming to let some recipients of a kidney from an HLA-matched sibling stop anti-rejection medicine.
Status: Phase 3 randomized trial published in Am J Transplant (Jul 2025), limited to HLA-matched living related transplants. 30
What this means for you now: Does not apply to most transplants. Never stop anti-rejection medicine on your own.
Hope vs hype: No published evidence establishes a generally safe way to stop anti-rejection medicine.
Last checked 15 Nov 2026
AI and prediction tools
Research models for biopsies, relapse risk and trial matching. None is a tool for patients to use on their own. AI in vasculitis and kidney care
Find a trial
Search ClinicalTrials.gov for microscopic polyangiitis or the EU trials register, and talk with your specialist first.31,32,33
Open questions researchers are working on
- How often does MPA recur after transplant in people diagnosed as children, and what predicts it?
- How should MPO-ANCA, urine markers and donor-specific antibodies be monitored together?
- Which steroid-sparing options preserve long-term kidney function with acceptable infection risk?
- How do kidney function, prior treatment and transplant medicines affect pregnancy outcomes?
- Which transition programs help young adults avoid gaps in care?
Research networks: Vasculitis Clinical Research Consortium, European Vasculitis Society, VPPRN.34,35,36
Sources
- U.S. FDA: Drug Safety Communication: serious liver injury in patients taking Tavneos (avacopan) [doc ref 18]
- U.S. FDA: CDER proposes to withdraw approval of TAVNEOS [doc ref 18]
- PubMed record of NEJM notice (29 Jun 2026): Retraction: Jayne DRW et al. Avacopan for the treatment of ANCA-associated vasculitis (ADVOCATE) [doc ref 19]
- European Medicines Agency: Tavneos: Article 20 referral (CHMP opinion and European Commission final decision) [doc ref 20]
- ClinicalTrials.gov: NCT07388277: CC-97540 (CD19 CAR T) in ANCA-associated vasculitis [doc ref 22]
- Rheumatology (2026): Anti-CD19 CAR T-cell therapy in ANCA-associated vasculitis (one patient with relapsing GPA)
- Kidney International Reports (2025): Point-of-care anti-CD19 CAR T-cell therapy induces renal remission in refractory MPO-ANCA vasculitis (letter, one patient) [doc ref 22]
- International Journal of Rheumatic Diseases (2026, congress abstract): Tandem CD19-BCMA CAR-T therapy in refractory ANCA-associated vasculitis
- Best Practice & Research Clinical Rheumatology (2026): CAR-T cell therapy for ANCA-associated vasculitis: rationale, current evidence, and future directions
- Genentech (press release, 19 Oct 2025): FDA approves Gazyva for lupus nephritis
- ClinicalTrials.gov: NCT07746180: obinutuzumab beta with low-dose glucocorticoid in new-onset ANCA glomerulonephritis [doc ref 24]
- BMJ Open (2024): ObiVas protocol: obinutuzumab versus rituximab in ANCA-associated vasculitis [doc ref 23]
- ClinicalTrials.gov: NCT06388941: iptacopan in active ANCA-associated vasculitis
- ASN Kidney Week 2026: Abstract SA-OR077: iptacopan in active AAV, interim renal-focused results (24 Oct 2026)
- InflaRx (press release, Nov 2021): Phase II IXCHANGE study of vilobelimab in AAV
- ClinicalTrials.gov: NCT07168161: BDB-001 phase III trial in ANCA-associated vasculitis
- InflaRx (press release, Nov 2026): InflaRx highlights izicopan development path in ANCA-associated vasculitis
- ClinicalTrials.gov: NCT07904806: VIS954 in ANCA-associated vasculitis [doc ref 41]
- EU Clinical Trials Information System: PREP-ANCA (2025-522049-23-00): surveillance vs pre-emptive rituximab when ANCA reappears [doc ref 41]
- Arthritis & Rheumatology (2019): BREVAS: belimumab and azathioprine for maintenance of remission in AAV [doc ref 42]
- NHS Health Research Authority: COMBIVAS research summary [doc ref 42]
- Nature Communications (2024): Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis
- ClinicalTrials.gov: NCT06685757: felzartamab in antibody-mediated kidney transplant rejection (TRANSCEND) [doc ref 25]
- ClinicalTrials.gov: NCT07444489: felzartamab long-term extension (TRANSCEND/TRANSPIRE LTE) [doc ref 43]
- Lancet Regional Health – Europe (2026): Felzartamab in antibody-mediated kidney transplant rejection: phase 2 extension [doc ref 26]
- Hansa Biopharma (press release, 18 Feb 2026): BLA for imlifidase accepted by the FDA
- Hansa Biopharma (press release, 4 Mar 2026): PDUFA action date for imlifidase BLA set for December 19, 2026
- ClinicalTrials.gov: NCT07835581: tegoprubart vs tacrolimus in kidney transplantation (LEGACY)
- Eledon via SEC EDGAR: Eledon third-quarter 2026 results (Exhibit 99.1)
- American Journal of Transplantation (2025): Induction of immune tolerance in living related HLA-matched kidney transplantation: phase 3 randomized trial [doc ref 27]
- ClinicalTrials.gov: Search: microscopic polyangiitis
- EU CTIS: Search for clinical trials
- ClinicalTrials.gov: Learn about clinical studies
- Vasculitis Clinical Research Consortium: VCRC team [doc ref 30]
- European Vasculitis Society: EUVAS
- Vasculitis Foundation: Vasculitis Patient-Powered Research Network (VPPRN)
Links checked 15 November 2026. Full list: all sources.